Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Harvard Business School
Moodys
Boehringer Ingelheim
Merck

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Fexinidazole

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Fexinidazole: Patents, clinical trial progress, indications

Fexinidazole is an investigational drug.

There have been 12 clinical trials for Fexinidazole. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Trypanosomiasis, Trypanosomiasis, African, and Chagas Disease. The leading clinical trial sponsors are Drugs for Neglected Diseases, Sanofi, and European and Developing Countries Clinical Trials Partnership (EDCTP).

There are twenty US patents protecting this investigational drug and one hundred and eighty-three international patents.

Recent Clinical Trials for Fexinidazole
TitleSponsorPhase
Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei RhodesienseEuropean and Developing Countries Clinical Trials Partnership (EDCTP)Phase 2/Phase 3
Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei RhodesienseDrugs for Neglected DiseasesPhase 2/Phase 3
Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas DiseaseDrugs for Neglected DiseasesPhase 2

See all Fexinidazole clinical trials

Clinical Trial Summary for Fexinidazole

Top disease conditions for Fexinidazole
Top clinical trial sponsors for Fexinidazole

See all Fexinidazole clinical trials

US Patents for Fexinidazole

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fexinidazole   Start Trial Boron-containing small molecules as antiprotozoal1 agents MMV MEDICINES FOR MALARIA VENTURE (Geneva, CH)   Start Trial
Fexinidazole   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
Fexinidazole   Start Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
McKinsey
Boehringer Ingelheim
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.